SCARNA11

Across TCGA pan-cancer cohorts, SCARNA11 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated SCARNA11 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SCARNA11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SCARNA11 expression acts as an unfavorable survival marker, although some lineages such as LAML and PAAD show a favorable association.

LIHC, LAML, and DLBC are the cancer types where SCARNA11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.362	0.628	.019	33	view →
LAML	DFS	Median	All	0.665	0.474	.009	30	view →
DLBC	OS	Tertile	All	0.528	0.945	.010	27	view →
PCPG	OS	Tertile	All	0.676	0.981	.004	24	view →
KICH	OS	Tertile	All	0.771	0.947	.009	19	view →
KIRP	OS	Tertile	All	0.422	0.756	.004	18	view →
PAAD	DFS	Tertile	All	0.511	0.229	.009	18	view →
KIRC	DFS	Tertile	IV	0.294	0.647	.001	18	view →
THCA	OS	Tertile	IV	0.790	1.000	.016	18	view →
READ	OS	Tertile	IV	0.289	0.899	<.001	15	view →
UVM	OS	Quartile	III,IV	0.367	0.959	<.001	14	view →
LGG	DFS	Quartile	All	0.758	0.848	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

SCARNA11–LIHC (OS)

Open the LIHC breakdown →